Introduction {#s1}
============

Complications arising from preterm labor account for 65% of neonatal deaths and 50% of neurologic disabilities worldwide. Advances in the care of preterm infants have dramatically increased rates of survival, which rise sharply from 1% at 23 weeks to 99% at 32 weeks. However, this is associated with a reciprocal increase in the risk of complications ([@B14]). Although advances have been made in the prediction and prevention of preterm birth in women identified at high risk based on past history, the overall rate has not decreased. The 2012 World Health Organization report *Born Too Soon* ([@B11]) highlighted the need for effective tocolytic drugs to delay preterm birth in women with preterm contractions.

Infection and/or inflammation is associated with activation of contractile pathways leading to both term and preterm labor. Furthermore, infection/inflammation and subsequent increases in proinflammatory cytokines were found to be one of the most potent causes of perinatal brain injury ([@B8]; [@B22]). In normal birth weight infants at term, chorioamnionitis and intrauterine exposure to maternal infection are associated with periventricular leukomalacia and cerebral palsy ([@B9]; [@B24]). In the case of established chorioamnionitis, it is possible that an effective tocolytic drug based solely on the inhibition of uterine contractions could result in prolonged exposure of the fetus to an adverse environment. Therefore, an optimal tocolytic should also have anti-inflammatory activity. Although the precise mechanisms responsible for initiating labor in humans remain ambiguous, it is well established that the oxytocin (OT)/oxytocin receptor (OTR) system plays a central role in the biochemistry of term/preterm labor. Functional OTR is expressed both in the myometrium and fetal membranes (amnion and chorion). OT is widely used for induction/augmentation of both preterm and term labor, and OT binding to its receptor leads to OTR coupling with both G*~α~*~q/11~ and G*~α~*~i/o~ G proteins ([@B20]). G*~α~*~q/11~ signaling in the myometrium activates phospholipase C to drive increases in intracellular Ca^2+^ via inositol triphosphate, ultimately leading to contractions. Previous studies showed that OTR signaling through G*~α~*~i/o~ reduces cAMP by inhibition of adenylate cyclase activity ([@B4]; [@B5]). We recently demonstrated a novel mechanism for OT driving proinflammatory effects in human gestational tissues ([@B12]). In the amnion, this was found to be via G*~α~*~i~ signaling, which leads to activation of mitogen-activated protein kinases (MAPKs) and nuclear factor-*κ*B (NF-*κ*B), and a subsequent increase in the expression of NF-*κ*B--regulated genes including prostaglandin (PG) synthetic enzymes and inflammatory chemokines/cytokines.

OTR antagonists are used in clinical practice for the treatment of preterm labor through inhibition of myometrial contractility, but their effect on the proinflammatory effects of OT has been largely ignored. We recently showed that these OT-driven proinflammatory effects in the amnion are not inhibited by atosiban. Conversely, atosiban alone results in activation of MAPKs and NF-*κ*B to the same extent as OT ([@B13]). Atosiban acts as a biased ligand to the G*~α~*~i~ pathway, which may limit its use to 48 hours ([@B5]; [@B10]), yet OTR still represents an attractive drug target for tocolysis. Indeed, with growing recognition of the complexity of G protein--coupled receptor (GPCR) signaling, there has been an impetus to design more specific compounds modulating GPCR action that show bias toward specific signaling pathways ([@B23]; [@B5]).

Clinical studies to date have used OTR antagonists for acute tocolysis rather than for the prevention of preterm labor in women at high risk for preterm delivery. The only OTR antagonist currently licensed in Europe is atosiban, which can only be given as a continuous intravenous infusion for no more than 48 hours and thus precludes long-term administration for maintenance therapy. Nolasiban is a novel, small-molecule, nonpeptide OTR antagonist. Nolasiban is selective for OTR against the arginine vasopressin (AVP) V1a and V2 receptors, whereas atosiban is primarily an AVP V1a antagonist ([@B16]). Whereas the currently available OTR antagonist atosiban is given via intravenous infusion, nolasiban is administered orally and thus lends itself to preterm labor treatment beyond 48 hours.

In this study, we investigated whether the OTR antagonist nolasiban can inhibit OT-driven activation of the inflammatory response in human gestational tissues, and we compared and contrasted the effects of nolasiban with the currently licensed OTR antagonist atosiban.

Materials and Methods {#s2}
=====================

 {#s3}

### Cell Culture. {#s4}

Placentas with fetal membranes and myometrial biopsies were collected from term (38--40 weeks of pregnancy), nonlaboring women with singleton pregnancies undergoing scheduled low-risk elective caesarean section. This study excluded individuals who had preexisting medical conditions, preeclampsia, and/or multiple pregnancies or had received uterotonics prior to their caesarean sections. Samples were collected after participants gave informed consent and the study was approved by the local research ethics committees of Queen Charlotte's and Chelsea Hospital (placenta, RREC 2002-6283; and myometrium, RREC 1997-5089).

The amnion layer from the placenta was pulled apart from the chorion to use for culture. Primary amnion epithelial cells were established from fetal membranes, as previously described ([@B2]). For myometrial smooth muscle cell isolation, the biopsies were dissected into fine pieces and digested in filter-sterilized collagenase mix \[1 mg/ml collagenase 1A, 1 mg/ml collagenase X, and 2 mg/ml bovine serum albumin in 1:1 ratio of Dulbecco's modified Eagle's medium (DMEM)/Ham's F-12 Nutrient Mixture and serum-free DMEM; Sigma-Aldrich, St. Louis, MO\] for 45 minutes at 37°C. The digestion process was halted using DMEM with 10% (v/v) fetal calf serum and the cell suspension was obtained by filtering out the tissue through a 40-*µ*m cell strainer (Corning, Corning, NY). Centrifugation of the suspension at 3000 rpm for 5 minutes collected the cells into a pellet, which was subsequently resuspended in full DMEM (10% fetal calf serum, 2 mM L-Glutamine, and 100 U/ml penicillin-streptomycin) and cultured in cell culture--treated flasks (Corning) at 37°C in humidified atmosphere of 95% air and 5% CO~2~. When myometrial cells reached 95% confluence, they were passaged using 0.25% trypsin with 0.02% EDTA in phosphate-buffered saline. We used myometrial cells between passage numbers one to four.

### Real-Time Polymerase Chain Reaction. {#s5}

Extraction of total RNA was carried out using RNA STAT-60 reagent for guanidinium thiocyanate--phenol--chloroform extraction (AMS Biotechnology, Abingdon, UK), following the manufacturer's recommended protocol. Any potential DNA contaminations were eliminated from the extracted RNA by DNase I treatment (Invitrogen, Carlsbad, CA) prior to cDNA synthesis. The DNase I--treated RNA was used for first-strand cDNA synthesis by Moloney murine leukemia virus reverse transcriptase (Sigma-Aldrich). Changes in gene expression were determined by real-time polymerase chain reaction with the ABI StepOne Plus Real-Time PCR system (Applied Biosystems, Foster City, CA) using SYBR Green JumpStart Taq ReadyMix (Sigma-Aldrich). Primer Express software (Applied Biosystems) was used to design specific primers for each gene. Sequences of the gene-specific primers are listed in [Table 1](#T1){ref-type="table"}. The resulting data were analyzed using StepOne software (version 2.3; Applied Biosystems). All primers were tested for efficiency, and the comparative cycle threshold method was used to analyze the relative changes in gene expression. Cycle threshold values for all target genes were normalized to constitutively expressed ribosomal protein L19 and also to glyceraldehyde 3-phosphate dehydrogenase for amnion and myometrial cells, respectively.

###### 

Primer sequences for real-time polymerase chain reaction

  Target Gene   Forward Primer Sequence (5′ to 3′)   Reverse Primer Sequence (5′ to 3′)
  ------------- ------------------------------------ ------------------------------------
  L19           GCGGAAGGGTACAGCCAAT                  GCAGCCGGCGCAAA
  GAPDH         TGATGACATCAAGAAGGTGGTGAAG            TCCTTGGAGGCCATGTAGGCCAT
  CCL2          TCTGTGCCTGCTGCTCATAG                 AGATCTCCTTGGCCACAATG
  CCL5          CCATATTCCTCGGACACCAC                 TGTACTCCCGAACCCATTTC
  COX-2         TGTGCAACACTTGAGTGGCT                 ACTTTCTGTACTGCGGGTGG
  IL-6          CCTTCCAAAGATGGCTGAAA                 AGCTCTGGCTTGTTCCTCAC
  IL-8          GCCTTCCTGATTTCTGCAGC                 CGCAGTGTGGTCCACTCTCA
  SOD2          TTGGCCAAGGGAGATGTTAC                 AGTCACGTTTGATGGCTTCC

GAPDH, glyceraldehyde 3-phosphate dehydrogenase; SOD, superoxide dismutase

### Western Blot Analysis. {#s6}

Whole-cell lysates were obtained by lysing the monolayer of cells in modified radioimmunoprecipitation assay buffer, containing 150 mM NaCl, 10 mM Tris (pH 7.4), 1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, and protease and phosphatase inhibitor cocktails (Sigma-Aldrich; Thermo Fisher, Rockford, IL). The concentration of each lysate was determined using a detergent compatible protein assay kit (Bio-Rad, Hercules, CA) and 40 *μ*g of each protein sample was denatured in loading dye with 50 mM dithiothreitol by heating for 10 minutes at 80°C. Proteins were separated by electrophoresis on a 10% SDS-polyacrylamide gel for 80 minutes at constant 140 V and were transferred to a polyvinylidene difluoride membrane (Millipore, Billerica, MA) in a wet-transfer chamber system (Bio-Rad) for 90 minutes at constant 300 mA. A precast midi-gel (Bio-Rad) was used to separate more than 15 protein samples. Polyvinylidene difluoride membranes were blocked in blocking buffer \[5% (w/v) milk powder in Tris-buffered saline with 0.1% Tween-20\] prior to primary antibody incubation overnight at 4°C. Horseradish peroxidase--conjugated secondary antibody incubation lasted for 1 to 2 hours at room temperature, and signal detection was carried out using an enhanced chemiluminescence reagent (Bio-Rad). To confirm equal loading of samples, membranes were treated with a mild stripping buffer (0.2 M NaOH) and reprobed for *β*-actin.

### Enzyme-Linked Immunosorbent Assay. {#s7}

Concentrations of PGE~2~ in the culture supernatants were determined by a standard enzyme-linked immunosorbent assay. At treatment completion, culture media from both myometrial and amnion cells were collected and immediately frozen for storage at −20°C until subsequent analysis by enzyme-linked immunosorbent assay, following the manufacturer's instructions (R&D Systems, Minneapolis, MN).

### Materials. {#s8}

Goat anti--cyclooxygenase (COX)-2 (C20) antibody (Santa Cruz Biotechnology, Dallas, TX) was used at 1:2000 dilution, and rabbit monoclonal antibodies to phosphorylated cytosolic phospholipase A~2~ (p-cPLA~2~), p-p65 (Ser536), p-MAPK14 (p38 MAPK), and p-MAPK3/1 (extracellular signal--regulated kinase ERK1/2 p44/42 MAPK) from Cell Signaling Technology (Danvers, MA) were used at 1:1000 dilution. The mouse monoclonal anti--*β*-actin antibody (at 1:50,000) was from Abcam (Cambridge, UK). Horseradish peroxidase--conjugated secondary antibodies against goat, mouse, and rabbit IgGs were from Santa Cruz Biotechnology. Oxytocin and atosiban were obtained from Alliance Pharmaceuticals (San Diego, CA) and Sigma-Aldrich, respectively. Nolasiban was synthesized as previously described ([@B7]). The nolasiban chemical formula is (3*Z*,5*S*)-5-(hydroxymethyl)-1-\[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl\]pyrrolidin-3-one *O*-methyloxime ([Fig. 1](#F1){ref-type="fig"}). Nolasiban is prepared following an eight-step synthesis starting from 4-bromobenzoic acid. A detailed description of nolasiban preparation is provided below.

![Chemical structure of nolasiban.](mol.116.106013f1){#F1}

A solution of potassium carbonate in water was charged to a slurry of 4-bromobenzoic acid in water at 15--25°C. The resulting slurry was stirred at 15--25°C and degassed three times using a vacuum-nitrogen purge cycle. Tetrakis(triphenylphosphine)palladium(0) was charged and the vacuum-nitrogen purge cycle was repeated. A solution of *o*-tolylboronic acid was degassed three times, using a vacuum-nitrogen purge cycle, and then charged to the 4-bromobenzoic acid slurry at 15--25°C. The reaction mixture was heated to and maintained at reflux until reaction completion (the reaction is considered complete at 95% conversion), as determined by proton nuclear magnetic resonance spectroscopy (^1^H NMR) analysis \[*d*~6~-dimethylsulfoxide (DMSO)\], typically 1.5--2.5 hours. After workup, the solid was dried in a vacuum oven at 35--40°C to give 4-(2-methylphenyl)benzoic acid \[^1^H NMR (*d*~6~-DMSO) concordant with structure\] as a pale yellow solid. Thionyl chloride was added to a slurry of 4-(2-methylphenyl)benzoic acid in toluene at 10--25°C and the mixture was heated to and maintained at 75--80°C until complete by ^1^H NMR analysis (*d*~6~-benzene), typically 4 to 5 hours. After workup, the toluene solution of 4-(2-methylphenyl)benzoic acid chloride \[^1^H NMR (*d*~6~-benzene) concordant with structure\] was used directly in the next step.

A solution of potassium carbonate was charged to a solution of 4-hydroxy-[l]{.smallcaps}-proline in tetrahydrofuran and water at 15--25°C followed by a line rinse of water. The mixture was cooled to 0--5°C with rapid stirring and a solution of 4-(2-methylphenyl)benzoic acid chloride in toluene was charged at that temperature followed by a line rinse of toluene. The reaction mixture was warmed to 15--25°C over 1 to 2 hours and stirred at this temperature until judged complete by thin layer chromatography (TLC) analysis. After workup, the collected solid was dried under vacuum at 40--45°C until the water content by Karl Fischer titration was ≤0.2% (w/w) to afford (4*R*)-4-hydroxy-1-\[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl\]-[l]{.smallcaps}-proline \[^1^H NMR (*d*~6~-DMSO) concordant with structure\] as an off-white solid.

Triethylamine was charged to a solution of (4*R*)-4-hydroxy-1-\[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl\]-[l]{.smallcaps}-proline in DMSO at 15--20°C. Pyridine-sulfur trioxide complex was charged portion-wise at 15 and 25°C and the reaction mixture was stirred at that temperature until reaction completion, as determined by TLC analysis (typically 1--3 hours). After workup, the collected solid was dried under vacuum at 40--45°C to give 1-\[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl\]-4-oxo-[l]{.smallcaps}-proline \[^1^H NMR (*d*~6~-DMSO) concordant with structure\] as an off-white solid.

Triethylamine was added to a solution of 1-\[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl\]-4-oxo-[l]{.smallcaps}-proline in dichloromethane at 10--25°C. Methoxylamine hydrochloride was added portion-wise at 10--25°C and the reaction mixture was stirred at 10--25°C until reaction completion, as determined by TLC analysis \[typically 3--5 hours, TLC eluent: dichloromethane/methanol/acetic acid (90:10:1); UV visualization\]. After workup, the filtrate and washes were combined and concentrated under vacuum at 35--40°C to afford 4-methoxyimino-1-\[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl\]-[l]{.smallcaps}-proline \[^1^H NMR (CDCl3) concordant with structure\] as an off-white solid.

Potassium carbonate was added to a solution of 4-methoxyimino-1-\[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl\]-[l]{.smallcaps}-proline and the mixture was cooled to 0--10°C. Dimethyl sulfate was added at 0--15°C and the mixture was stirred at 15--25°C until reaction completion, as determined by TLC analysis, typically 3--16 hours. After workup, excess ethyl acetate was removed by azeotropic distillation with tetrahydrofuran under vacuum at 40--45°C to give (4*Z*/*E*,2*S*)-methyl-1-\[(2′-methyl-1,1′-biphenyl-4-yl)-carbonyl\]-4-methoxyimino pyrrolidine-2-carboxylate \[^1^H NMR (CDCl3) concordant with structure\] as a viscous brown oil.

Lithium borohydride was added portion-wise under nitrogen to a stirred solution of (4*Z*/*E*,2*S*)-methyl-1-\[(2′-methyl-1,1′-biphenyl-4-yl)-carbonyl\]-4-methoxyimino pyrrolidine-2-carboxylate in tetrahydrofuran and methanol at 0--30°C. The prepared mixture was stirred at 15--25°C to reaction completion, as determined by TLC analysis (eluent: ethyl acetate; visualization: ninhydrin), typically 2--6 hours. After workup, the combined filtrate and wash were concentrated under vacuum to give a crude isomeric mixture comprising (3*Z*,5*S*)-5-(hydroxymethyl)-1-\[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl\]pyrrolidin-3-one *O*-methyloxime and (3*E*,5*S*)-5-(hydroxymethyl)-1-\[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl\]pyrrolidin-3-one *O*-methyloxime \[^1^H NMR (CDCl3) concordant with structure; 82.0% area by high-pressure liquid chromatography, 71.4:28.6 *Z*/*E* ratio\] as a viscous brown oil. The oil was dissolved in toluene and stored until required. Pure nolasiban or (3*Z*,5*S*)-5-(hydroxymethyl)-1-\[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl\]pyrrolidin-3-one *O*-methyloxime was isolated by chromatography and elution with toluene/MeOH \[99:1 (v/v)\].

The vehicle controls for OT, atosiban and nolasiban were DMEM (Sigma-Aldrich), double deionized water, and DMSO, respectively. Nolasiban was diluted from stock solutions using DMEM shortly prior to the treatments. The DMSO concentration was adjusted to 0.1% (v/v) in all dose formulations and control wells for nolasiban experiments were treated to contain 0.1% (v/v) DMSO.

### Statistical Analysis. {#s9}

GraphPad Prism software (version 5.0; GraphPad Inc., La Jolla, CA) was used for statistical analysis. We tested our data sets for normality using the Kolmogorov--Smirnov test prior to appropriate statistical comparisons. When data were normally distributed, multiple comparisons were performed using analysis of variance, followed by the Tukey--Kramer (or the Tukey honest significant difference) post hoc test. For non-normally distributed data, multiple comparisons were performed using the Freidman test, followed by the Dunn multiple comparisons post hoc test. In this study, all data sets are presented as means ± S.E.M. and differences were considered statistically significant at *P* \< 0.05.

Results {#s10}
=======

 {#s11}

### Atosiban Has No Effect on OT-Mediated Upregulation of Proinflammatory Mediators But Mimics the Effects of OT in Human Amnion. {#s12}

We previously demonstrated that the presence of atosiban in amnion cells has no significant effect on the OT-driven activation of NF-*κ*B and MAPKs and the upregulation of downstream prolabor genes at an OT concentration of 100 nM ([@B13]). In this study, amnion cells were treated with atosiban and a lower dose of OT (10 nM), which is more physiologically relevant. There was no significant inhibition of OT effects in the presence of atosiban; similar to recently published data, atosiban consistently led to activation of proinflammatory mediators including NF-*κ*B and MAPKs and subsequent expression of PG synthetic enzymes COX-2 and p-cPLA~2~ ([Fig. 2](#F2){ref-type="fig"}).

![The effect of atosiban on OT-induced proinflammatory responses in amnion cells. Prelabor amnion epithelial cells were stimulated for 5 minutes, 15 minutes, 30 minutes, 2 hours, 4 hours, and 6 hours with atosiban (10 *μ*M) and/or OT (10 nM). (A and B) Representative Western blots for the phosphorylated NF-*κ*B p65 subunit, ERK1/2, and p38 MAPK (A), as well as COX-2 and p-cPLA~2~ (B), are shown above their corresponding densitometry graphs with fold changes compared with NS controls. Matched *β*-actin loading controls confirm equal loading (*n* = 6; \**P* \< 0.05; \*\**P* \< 0.01 compared with NS). Significance was tested using ANOVA, with correction for multiple testing by the Tukey--Kramer multiple comparisons test. ANOVA, analysis of variance; Ato, atosiban; NS, nonstimulated.](mol.116.106013f2){#F2}

These effects of atosiban translated to changes in the expression of downstream NF-*κ*B--regulated genes. The presence of atosiban did not inhibit OT-mediated expression of COX-2, interleukin (IL)-6, C-C motif chemokine ligand CCL5, IL-8, and superoxide dismutase 2 at the mRNA level ([Fig. 3](#F3){ref-type="fig"}). Furthermore, atosiban treatment alone resulted in 2.8-, 2.3-, and 2.4-fold increases in the expression of COX-2, IL-6, and CCL5 (all *P* \< 0.05), respectively ([Fig. 3, A--C](#F3){ref-type="fig"}).

![Increase in prolabor NF-*κ*B--regulated gene expression with atosiban stimulation in amnion cells. Prelabor amnion epithelial cells were stimulated for 1 hour, 2 hours, 4 hours, and 6 hours with atosiban (10 *μ*M) and/or OT (10 nM). (A--E) The expression of downstream NF-*κ*B--regulated genes, COX-2 (A), IL-6 (B), CCL5 (C), IL-8 (D), and SOD2 (E), was examined from total RNA extracts. Atosiban had no effect on OT-induced upregulation, but atosiban alone increased the expression of COX-2, IL-6, and CCL5 (*n* = 6; \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001 compared with NS; ANOVA). Significance was tested using ANOVA, with correction for multiple testing by the Tukey--Kramer multiple comparisons test. ANOVA, analysis of variance; Ato, atosiban; NS, nonstimulated; SOD, superoxide dismutase.](mol.116.106013f3){#F3}

### Unlike Atosiban, Nolasiban Suppresses the Effects of OT on Proinflammatory Mediators Including Activation of NF-*κ*B and MAPKs and Prolabor Gene Expression in Human Amnion. {#s13}

Matching experiments in amnion cells using nolasiban showed markedly different results to atosiban. The presence of nolasiban led to a significant reduction in OT-driven activation of both NF-*κ*B p65 and p38 kinases at an equimolar concentration of atosiban as well as at lower doses ([Fig. 4, A--C](#F4){ref-type="fig"}). There was a slight reduction in OT-induced ERK1/2 activation in a dose-dependent manner; however, this did not reach significance ([Fig. 4D](#F4){ref-type="fig"}). Nolasiban alone did not have a significant effect on NF-*κ*B and p38 activation or expression of PG synthetic enzymes ([Supplemental Fig. 1](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.116.106013/-/DC1)). However, at the maximum dose of nolasiban (30 *µ*M), we observed activation of ERK1/2 (*P* \< 0.001) with no effect on downstream targets; this indicates that at this high concentration of nolasiban (which is physiologically irrelevant), the effect may be due to activation of an alternative signaling pathway, independent to that of OT.

![The effect of nolasiban on OT-mediated activation of NF-*κ*B and MAPKs in amnion cells. Prelabor primary amnion epithelial cells were stimulated with OT (10 nM) in the presence or absence of nolasiban (1, 3, or 10 *µ*M) for 5 minutes, 15 minutes, and 30 minutes. (A) Western blots were used to examine the effect of nolasiban on OT-mediated activation of p65 NF-*κ*B and MAPKs, ERK1/2, and p38 MAPK. Solid lines indicated cropping boundaries of strips (please note that this editing is also done in the blot panels in [Figs. 5A](#F5){ref-type="fig"}, [10A](#F10){ref-type="fig"}, and [11A](#F11){ref-type="fig"}). NS controls and OT-only treatments were adjusted to contain the vehicle, DMSO, at 0.1% (v/v). *β*-actin confirmed equal protein loading. (B--D) Densitometric analyses showed significant decreases in OT-mediated activation of p65 (B) and p38 (C) in the presence of nolasiban, but not ERK1/2 (D) (*n* = 6; \**P* \< 0.05 versus NS; ^\#^*P* \< 0.05 versus OT-treated samples; ANOVA). Significance was tested using ANOVA, with correction for multiple testing by Tukey-Kramer multiple comparisons test. ANOVA, analysis of variance; Nol, nolasiban; NS, nonstimulated.](mol.116.106013f4){#F4}

Treatment of amnion cells with nolasiban also completely inhibited OT-mediated expression of PG synthetic enzymes COX-2 and p-cPLA~2~ from the lowest dose of 1 *µ*M (*P* \< 0.05 and *P* \< 0.001, respectively; [Fig. 5](#F5){ref-type="fig"}) and, consequently, OT-mediated PGE~2~ release (*P* \< 0.001; [Fig. 6](#F6){ref-type="fig"}). Further experiments looking at the mRNA expression of other NF-*κ*B-- regulated genes revealed a clear dose-dependent inhibitory effect of nolasiban on COX-2, IL-6, CCL5, IL-8, CCL2, and superoxide dismutase 2 ([Fig. 7](#F7){ref-type="fig"}).

![The effect of nolasiban on OT-mediated expression of PG synthetic enzymes in amnion cells. Prelabor primary amnion epithelial cells were stimulated with OT (10 nM) in the presence or absence of nolasiban (1, 3, or 10 *µ*M) for 2 hours, 4 hours, and 6 hours. (A) Western blots were used to examine the effect of nolasiban on OT-mediated expression of COX-2 and p-cPLA~2~. NS controls and OT-only treatments were adjusted to contain the vehicle, DMSO, at 0.1% (v/v). *β*-actin confirmed equal protein loading. (B and C) Densitometric analyses showed significant decreases in OT-mediated expression of COX-2 (B) and p-cPLA~2~ (C) in the presence of nolasiban (*n* = 6; \*\*\**P* \< 0.001 versus NS; ^\#^*P* \< 0.05; ^\#\#^*P* \< 0.01; ^\#\#\#^*P* \< 0.001 versus OT-treated samples; ANOVA). Significance was tested using ANOVA, with correction for multiple testing by the Tukey--Kramer multiple comparisons test. ANOVA, analysis of variance; Nol, nolasiban; NS, nonstimulated.](mol.116.106013f5){#F5}

![The effect of nolasiban on OT-mediated PGE~2~ release in amnion cells. Prelabor primary amnion epithelial cells were stimulated with OT (10 nM) in the presence or absence of nolasiban (1, 3, 10, or 30 *µ*M) for 2 hours, 4 hours, and 6 hours. The PGE~2~ enzyme-linked immunosorbent assay demonstrated a significant inhibition of OT-mediated PGE~2~ production by nolasiban (*n* = 6; \**P* \< 0.05; \*\*\**P* \< 0.001 versus NS; ^\#\#\#^*P* \< 0.001 versus OT-treated samples; ANOVA). Significance was tested using ANOVA, with correction for multiple testing by the Dunn multiple comparisons test. ANOVA, analysis of variance; Nol, nolasiban; NS, nonstimulated.](mol.116.106013f6){#F6}

![The effect of nolasiban on OT-mediated expression of downstream NF-*κ*B--regulated genes in amnion cells. (A--F) Prelabor primary amnion epithelial cells were treated with OT (10 nM) in the presence or absence of nolasiban (1, 3, 10, or 30 *µ*M) for 1 hour, 2 hours, 4 hours, 6 hours, and 24 hours, and changes in the expression of downstream NF-*κ*B--regulated genes, COX-2 (A), IL-8 (B), IL-6 (C), CCL5 (D), CCL2 (E), and SOD2 (F), were analyzed using qRT-PCR. For qRT-PCR analysis, target gene mRNA levels were normalized to that of the housekeeping gene, L19 (*n* = 4; \**P* \< 0.05; \*\*\**P* \< 0.001 versus NS; ^\#^*P* \< 0.05 versus OT-treated samples; ANOVA). Significance was tested using ANOVA, with correction for multiple testing by the Tukey--Kramer multiple comparisons test. ANOVA, analysis of variance; Nol, nolasiban; qRT-PCR, quantitative real-time polymerase chain reaction; SOD, superoxide dismutase.](mol.116.106013f7){#F7}

### Atosiban Acts as a Partial Inhibitor of OT-Mediated Responses, But It Alone Consistently Activates NF-*κ*B and ERK1/2, While Inducing CCL5 Expression in Human Myometrium. {#s14}

In contrast with our findings in human amnion, treatment with atosiban significantly reduced the OT-driven activation of p38 kinase and the upregulation of COX-2 in human myometrial cells ([Fig. 8](#F8){ref-type="fig"}). However, despite these inhibitory effects, atosiban failed to suppress the effect of OT on NF-*κ*B and ERK1/2 activation and resulted in activation of both NF-*κ*B and ERK1/2 in the absence of OT ([Fig. 8](#F8){ref-type="fig"}).

![The effect of atosiban on OT-induced proinflammatory responses in myometrial cells. Prelabor myometrial smooth muscle cells were stimulated with OT (10 nM) for 5 minutes, 15 minutes, 30 minutes, 2 hours, 4 hours, and 6 hours in the presence or absence of atosiban (10 *μ*M). (A and B) Representative Western blots for the phosphorylated NF-*κ*B p65 subunit, ERK1/2, and p38 MAPK (A), as well as COX-2 and p-cPLA~2~ (B), are shown above their corresponding densitometry graphs with fold changes compared with nonstimulated controls. Matched *β*-actin loading controls confirm equal loading (*n* = 6; \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001 compared with NS; ANOVA). Significance was tested using ANOVA, with correction for multiple testing by the Tukey--Kramer multiple comparisons test. ANOVA, analysis of variance; Ato, atosiban; NS, nonstimulated.](mol.116.106013f8){#F8}

The presence of atosiban showed variable effects on the expression of downstream NF-*κ*B--regulated genes. Complementary to the findings in COX-2 expression at the protein level, atosiban successfully inhibited the OT-induced mRNA expression of COX-2 and IL-8 ([Fig. 9, A and D](#F9){ref-type="fig"}). There was a marginal reduction in OT-induced IL-6 expression, but it did not reach statistical significance ([Fig. 9B](#F9){ref-type="fig"}). Of particular note were the changes in the mRNA expression of CCL5, which increased with atosiban in the absence of OT stimulation ([Fig. 9C](#F9){ref-type="fig"}).

![The effect of atosiban on OT-induced upregulation of NF-*κ*B--regulated genes in myometrial cells. Prelabor myometrial smooth muscle cells were stimulated for 1 hour, 2 hours, 4 hours, and 6 hours with atosiban (10 *μ*M) and/or OT (10 nM). (A--E) The expression of downstream NF-*κ*B--regulated genes, COX-2 (A), IL-6 (B), CCL5 (C), IL-8 (D), and SOD2 (E), was examined from total RNA extracts. Atosiban inhibited the effect on OT-induced upregulation of COX-2, IL-6, and IL-8 but failed to inhibit CCL5 expression and it alone increased the expression of CCL5 (*n* = 6; \**P* \< 0.05 versus NS; ^\#^*P* \< 0.05 versus OT-treated samples; ANOVA). Significance was tested using ANOVA, with correction for multiple testing by the Tukey--Kramer multiple comparisons test. ANOVA, analysis of variance; Ato, atosiban; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NS, nonstimulated; SOD, superoxide dismutase.](mol.116.106013f9){#F9}

### Similar to Amnion, Nolasiban Suppresses the Effects of OT on Proinflammatory Mediators in Human Myometrium. {#s15}

Myometrial smooth muscle cells were incubated with increasing doses of nolasiban with or without OT stimulation. The OTR antagonist (nolasiban) alone had no significant effect on the OT-induced activation of NF-*κ*B and MAPKs, and the presence of nolasiban blocked the effects of OT on NF-*κ*B and p38 kinase, reaching significance at the 10-*µ*M dose (*P* \< 0.01; [Fig. 10](#F10){ref-type="fig"}). Moreover, nolasiban suppressed the OT-driven upregulation of COX-2 and p-cPLA~2~ ([Fig. 11](#F11){ref-type="fig"}), ultimately leading to the reduction of PGE~2~ synthesis ([Fig. 12](#F12){ref-type="fig"}). In addition to COX-2 expression, nolasiban also resulted in suppression of other NF-*κ*B--regulated genes, IL-8, IL-6, and CCL5, in a dose-dependent manner ([Fig. 13, A--D](#F13){ref-type="fig"}). Similar to amnion, nolasiban treatment alone in the myometrium had no effect on activation of NF-*κ*B and p38 or expression of PG synthetic enzymes ([Supplemental Fig. 2](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.116.106013/-/DC1)). At the 30-*µ*M dose, nolasiban activated ERK1/2 (*P* \< 0.01) without affecting the expression of downstream targets such as COX-2 and p-cPLA~2~.

![The effect of nolasiban on OT-mediated activation of NF-*κ*B and MAPKs in myometrial cells. Prelabor primary myometrial smooth muscle cells were stimulated with OT (10 nM) in the presence of absence of nolasiban (1, 3, or 10 *µ*M) for 5 minutes, 15 minutes, and 30 minutes. (A) Western blots were used to examine the effect of nolasiban on OT-mediated activation of p65 NF-*κ*B and MAPKs, ERK, and p38. NS controls and OT-only treatments were adjusted to contain the vehicle, DMSO, at 0.1% (v/v). *β*-actin confirmed equal protein loading. (B--D) Densitometric analyses showed significant decreases in OT-mediated activation of p65 (B) and p38 (C) in the presence of nolasiban, but not ERK1/2 (D) (*n* = 6; \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001 versus NS; ^\#\#^*P* \< 0.01 versus OT-treated samples; ANOVA). Significance was tested using ANOVA, with correction for multiple testing by the Tukey--Kramer multiple comparisons test. ANOVA, analysis of variance; Nol, nolasiban; NS, nonstimulated.](mol.116.106013f10){#F10}

![The effect of nolasiban on OT-mediated expression of PG synthetic enzymes in myometrial cells. Prelabor primary myometrial smooth muscle cells were stimulated with OT (10 nM) in the presence or absence of nolasiban (1, 3, or 10 *µ*M) for 2 hours, 4 hours, and 6 hours. (A) Western blots were used to examine the effect of nolasiban on OT-mediated expression of COX-2 and p-cPLA~2~. NS controls and OT-only treatments were adjusted to contain the vehicle, DMSO, at 0.1% (v/v). *β*-actin confirmed equal protein loading. (B and C) Densitometric analyses showed significant decreases in OT-mediated expression of COX-2 (B) and p-cPLA~2~ (C) in the presence of nolasiban (*n* = 6; \*\**P* \< 0.01; \*\*\**P* \< 0.001 versus NS; ^\#\#^*P* \< 0.01; ^\#\#\#^*P* \< 0.001 versus OT-treated samples; ANOVA). Significance was tested using ANOVA, with correction for multiple testing by the Tukey--Kramer multiple comparisons test. ANOVA, analysis of variance; Nol, nolasiban; NS, nonstimulated.](mol.116.106013f11){#F11}

![The effect of nolasiban on OT-mediated PGE~2~ release in myometrial cells. Prelabor primary myometrial smooth muscle cells were stimulated with OT (10 nM) in the presence or absence of nolasiban (1, 3, 10, or 30 *µ*M) for 2 hours, 4 hours, and 6 hours. The PGE~2~ enzyme-linked immunosorbent assay demonstrated a significant inhibition of OT-mediated PGE~2~ production by nolasiban (*n* = 6; \*\**P* \< 0.01; \*\*\**P* \< 0.001 versus NS; ^\#\#^*P* \< 0.01; ^\#\#\#^*P* \< 0.001 versus OT-treated samples; ANOVA). Significance was tested using ANOVA, with correction for multiple testing by the Dunn multiple comparisons test. ANOVA, analysis of variance; Nol, nolasiban; NS, nonstimulated.](mol.116.106013f12){#F12}

![The effect of nolasiban on OT-mediated expression of downstream NF-*κ*B--regulated genes in myometrial cells. Prelabor primary myometrial smooth muscle cells were treated with OT (10 nM) in the presence or absence of nolasiban (1, 3, 10, or 30 *µ*M) for 1 hour, 2 hours, 4 hours, 6 hours, and 24 hours, and the expression of downstream NF-*κ*B--regulated genes, COX-2 (A), IL-8 (B), IL-6 (C), CCL5 (D), CCL2 (E), and SOD2 (F), was analyzed using qRT-PCR. For qRT-PCR analysis, target gene mRNA levels were normalized to that of the housekeeping gene, GAPDH (*n* = 4; \**P* \< 0.05; \*\*\**P* \< 0.001 versus NS; ^\#^*P* \< 0.05 versus OT-treated samples; ANOVA). Significance was tested using ANOVA, with correction for multiple testing by the Tukey--Kramer multiple comparisons test. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; Nol, nolasiban; NS, nonstimulated; qRT-PCR, quantitative real-time polymerase chain reaction; SOD, superoxide dismutase.](mol.116.106013f13){#F13}

Discussion {#s16}
==========

Here, we investigated the effect of nolasiban, a novel orally active OTR antagonist, on OT-driven activation of inflammatory responses in human gestational tissues. We previously showed that OT activates a cassette of inflammatory mediators in both human amnion and myometrium, demonstrating a role for OT as an endogenous inflammatory signaling molecule ([@B12]). Atosiban, an OTR antagonist, is used in clinical practice in Europe for the treatment of preterm labor, and other OTR antagonists are in clinical trials. Although OTR antagonists can inhibit myometrial contractility, they appear to have differential effects upon mediators of inflammation within the gestational tissues. The OTR antagonist atosiban was shown previously to inhibit myometrial contractility ([@B19]); however, atosiban only acts as a partial inhibitor of OT-mediated proinflammatory responses in human myometrium and has a purely stimulatory effect and no inhibitory effect in human amnion. We have shown that in contrast with atosiban, nolasiban suppresses OT-mediated proinflammatory effects in both human amnion and myometrium ([Fig. 14](#F14){ref-type="fig"}).

![Schematic diagram describing the effects of OT, atosiban, and nolasiban on downstream signaling pathways in both human amnion and myometrium. Our data indicate that in the amnion, atosiban mimics the proinflammatory effects of OT, whereas nolasiban completely inhibits the effects of OT. In the myometrium, atosiban appears to show biased agonist properties in which it acts as an antagonist to inhibit myometrial contractions while driving expression of the NF-*κ*B--regulated gene, CCL5. Similar to amnion, nolasiban appeared to inhibit both the inflammatory and contractile effects of OT.](mol.116.106013f14){#F14}

We previously showed that there are differences in the OT-mediated activation of NF-*κ*B between the amnion and myometrium, which are associated with differential NF-*κ*B subunit translocation and MAPK crosstalk. In the myometrium, OT-driven NF-*κ*B activation resembles a canonical NF-*κ*B signaling pathway involving both p65 and p50 translocation. OT-induced NF-*κ*B activation in the amnion involves nuclear translocation of p65 but not p50, and requires ERK1/2 and p38 activation ([@B12]). Such tissue-specific signaling may provide an explanation for the variable effects of atosiban in the amnion and myometrium: atosiban acts as an "antilabor" agent though inhibition of OT-induced contractility in the myometrium, whereas it acts as a "prolabor agent" in the amnion and partially so in the myometrium, possibly via differential OTR G-protein coupling in the two cell types. In the amnion, atosiban has no inhibitory effect and, notably, it alone mimics the proinflammatory effects of OT. In the myometrium, atosiban significantly reduces OT-driven activation of p38 kinase and upregulation of COX-2 and IL-8, but it remains unable to suppress the effect of OT on NF-*κ*B and ERK1/2 activation and increases CCL5 expression regardless of OT stimulation. The data presented here show that, unlike atosiban, nolasiban completely inhibits all OT-mediated responses and suppresses expression and activation of proinflammatory mediators both in the amnion and myometrium without any downstream effects when treated alone. Despite the complete inhibition of OT-induced COX-2 upregulation and PGE~2~ levels in the presence of nolasiban, relatively high levels of PGE~2~ were detected in samples treated with nolasiban and OT at earlier time points. This may be due to the release of PGE~2~ rather than synthesis, as nolasiban successfully inhibits COX-2 expression as early as 2 hours. There have been reports in rat models in which OT was able to stimulate immediate pulsatile release of PGE~2~ via Ca^2+^ responses ([@B6]).

Preterm and term labor are characterized by a marked inflammatory cascade ([@B17]; [@B21]) associated with the upregulation of proinflammatory cytokines and chemokines, such as IL-1*β*, IL-6, IL-8, CCL2, and CCL5, in both human amnion and myometrium. The amnion is an important site of PG and proinflammatory cytokine/chemokine release and leads to fetal membrane remodeling and cervical ripening ([@B12]). Fetal membrane activation is considered to be a prelude to the onset of labor ([@B15]). This involves activation of inducible NF-*κ*B and the upregulation of prolabor proinflammatory genes such as COX-2 and OTR ([@B15]). We previously demonstrated that treatment with OT drives a similar set of inflammatory gene expressions as those in amnion activation, indicating that OT may act as an endogenous inflammatory signaling molecule in human gestational tissues ([@B12]).

Knowledge of GPCRs continues to evolve, and the diversity of its actions and complexity of its signaling mechanisms are becoming increasingly evident ([@B3]). The biology of the OT/OTR system appears to be no exception. Nolasiban is a novel orally active, small-molecule, nonpeptide OTR antagonist that is more selective for OTR than atosiban, as it binds to the human OTR with a *K*~i~ of 52 nM and is 2.5- and 50-fold selective against AVP V1a and V2 receptors, respectively. We previously showed that nolasiban can dose-dependently inhibit spontaneous and OT-stimulated contractions, affecting the rate, contraction peak, tension, and contraction duration to a similar extent as atosiban ([@B1]). Unlike atosiban, inhibition of uterine contractions by nolasiban did not evoke a proinflammatory signaling pathway; therefore, nolasiban appears to be a pure OTR antagonist, blocking both G*~α~*~i~- and G*~α~*~q~-mediated OT signaling in both the amnion and myometrium.

Early preterm birth, typically classified as delivery before 34 weeks of gestation, is often associated with infection and/or inflammation. It is now recognized that cytokine-mediated cerebral injury represents an important cause of prematurity-linked complications; thus, inflammation within the uterus is an important risk factor for fetal and neonatal central nervous system damage and poor outcomes ([@B18]). Therefore, it is crucial that any tocolytic agent used in acute preterm labor, including those modulating the OT/OTR system, should evade activation or aggravation of inflammation. Our study indicates that nolasiban is a promising new tocolytic, as it has the ability to not only inhibit myometrial contractility but it can also suppress the OT-mediated proinflammatory responses in human gestational tissues.
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